- Fee assured
- Verified this account
Mike Dennis is an established national expert in myeloid disease, a committee member of the NCRN working groups for AML and myelodysplasia, where his roles include Chief investigator (Li1) and Co-chief investigator (AML 19).
His research focus is around clinical trial development for optimal therapy in AML of traditional and emerging agents, from site development and delivery of phase 1 studies to international trial governance and oversight.
He was appointed as a Consultant Haematologist at The Christie, Manchester in 2004. He qualified in Medicine from the University of Dundee, completed his physician’s training in Liverpool before undertaking his first Haematology post in Australia. He then completed his Haematology training, including a MD, from the University of Liverpool.
Areas of interest
• Leukaemias (AML and CML)
• Myelodysplastic syndrome (MDS)
• Myeloproliferative disorders (Myelofibrosis, ET...)
• Aplastic aneamia
• Bone marrow transplantation
- MB ChB University of Dundee 1991
- MRCP Royal College of Physicians, Edinburgh 1996
- FRCPath Royal College of Pathologists, London 2003
- MD University of Liverpool 2003
Reference number 3542754
Professional bodies (positions held - last 3 yrs)
- Pathway Clinical Director Manchester Cancer 2015
Affiliations / memberships
American Society of Hematology, British Society for Haematology, the Royal College of Physicians, the Royal College of Pathologists and the European group for Blood and Marrow Transplantation (EBMT). A national committee member of both the AML and myelodysplasia (MDS) working groups of the National Cancer Research Network (NCRN)
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.